Evidence map›Paper›PMID 34522277›Full record

ArticleArchives of medical science : AMS2021

Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia.

Quanfu Li, Gaowa Jin, Caihong Jiang, Zewei Zhang, Jixiang Hou, Juan Zhao, Feng Chen, Zhenhao Li

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07647029 (A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07647029 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae

TypeinterventionalSponsorFudan UniversityRan2026 to 2028Enrolled126ConditionsBreast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)ArmsContinuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Quanfu LiDepartment of Medical Oncology, Ordos Central Hospital, China.
Gaowa JinDepartment of Medical Oncology, Ordos Central Hospital, China.
Caihong JiangDepartment of Medical Oncology, Ordos Central Hospital, China.
Zewei ZhangDepartment of Radiation Oncology, Sun Yat-sen University Cancer Centre; State Key Laboratory of Oncology in South China; Collaborative Innovation Centre for Cancer Medicine, China.
Jixiang HouDepartment of Medical Oncology, Ordos Central Hospital, China.
Juan ZhaoDepartment of Medical Oncology, Ordos Central Hospital, China.
Feng ChenDepartment of Medical Oncology, Ordos Central Hospital, China.
Zhenhao LiSchool of Public Health and Management, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Sun Yat-sen University · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34522277
PMCPMC8425230
OpenAlexW3191659307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.